JASPER THERAPEUTICS, INC. Proceeds from Common Stock Issued
JASPER THERAPEUTICS, INC. (JSPR) reported Proceeds from Common Stock Issued of $6.50 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-14
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $6.50M.
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $514.00K.
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2025 was $6.45M, a 86.32% decline from fiscal 2024.
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2024 was $47.20M, a 53.49% decline from fiscal 2023.
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2023 was $101.48M, a 362325.00% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2022 was $28.00K.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 5 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $6.50M 10-Q · filed 2026-05-14 | $6.50M derived: sum of 2 quarters · filed 2026-05-14 | $7.01M derived: sum of 3 quarters · filed 2026-05-14 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $514.00K derived: sum of 2 quarters · filed 2026-03-30 | $6.45M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $514.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $6.45M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $5.94M 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 derived: sum of 3 quarters · filed 2025-11-10 | $47.20M 10-K · filed 2025-02-28 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $47.20M 10-Q · filed 2025-11-10 | $47.20M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $47.20M 10-Q · filed 2025-08-13 | $47.20M derived: sum of 3 quarters · filed 2025-08-13 | $47.20M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $47.20M 10-Q · filed 2025-05-12 | $47.20M derived: sum of 2 quarters · filed 2025-05-12 | $47.20M derived: sum of 3 quarters · filed 2025-05-12 | $47.20M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $101.48M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $101.48M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $101.48M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $101.48M 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | $28.00K 10-K · filed 2023-03-08 | ||||
| 2019-12-31 | $98.00M 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |